Register
Journal Updates
eMediNexus Coverage from: 
Lorlatinib approved for ALK+ metastatic lung cancer
eMediNexus,  06 November 2018
remove_red_eye 717 Views
#Internal Medicine #Oncology #Pathology and Lab Medicine

0 Read Comments                

The US Food and Drug Administration (FDA) has approved lorlatinib (Lorbrena, Pfizer) for use in the treatment of patients with metastatic non–small cell lung cancer (NSCLC) whose tumors test positive for anaplastic lymphoma kinase (ALK+).
Read the full story.
Create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now